Sarvodaya Healthcare partners with Transcell Oncologics to offer predictive genetic analysis in Delhi

HEMATO PREGEN is predictive genetic analysis of the genetic material (RNA/DNA) in body to identify the genetic anomalies that cause up to 90 per cent of genetic diseases in humans

Sarvodaya Hospital and Transcell Oncologics, a stem cell technology-based biotech company, have announced that HEMATO PREGEN , a comprehensive test providing predictive health signature analysis services from Transcell, will now be available at Sarvodaya Medicentre in New Delhi.

HEMATO PREGEN is predictive genetic analysis of the genetic material (RNA/DNA) in body to identify the genetic anomalies that cause up to 90 per cent of genetic diseases in humans. The COVID pandemic has shown that many people who lost their lives or got severely ill were in fact in good physical health and were not having any serious disease. Many of them were regular at gyms and exercise and maintaining a good diet and lifestyle. For most such cases, the logical explanation is genetic anomalies which got triggered, leading to medical conditions that required extensive and expensive treatment, including hospitalisation or even death.

HEMATO PREGEN provides analysis of 20,000+ genes, which are known as predictive biomarkers, covering 90 per cent of diseases resulting from gene anomalies. The test is based on Next Generation/Whole Exome Sequencing (NGS/WES) and assessment by GenePoweRx, a homegrown trained Bioinformatics Engine with AI & ML tools and endorsed by Memorial Sloan Kettering Cancer Center, USA, in line with the Broad Institute’s human genome project. The report takes up to 45 days and a post-counselling session is offered at the clinic thereafter.